1
|
Chauveau F, Winkeler A, Chalon S, Boutin H, Becker G. PET imaging of neuroinflammation: any credible alternatives to TSPO yet? Mol Psychiatry 2024:10.1038/s41380-024-02656-9. [PMID: 38997465 DOI: 10.1038/s41380-024-02656-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 06/26/2024] [Accepted: 07/01/2024] [Indexed: 07/14/2024]
Abstract
Over the last decades, the role of neuroinflammation in neuropsychiatric conditions has attracted an exponentially growing interest. A key driver for this trend was the ability to image brain inflammation in vivo using PET radioligands targeting the Translocator Protein 18 kDa (TSPO), which is known to be expressed in activated microglia and astrocytes upon inflammatory events as well as constitutively in endothelial cells. TSPO is a mitochondrial protein that is expressed mostly by microglial cells upon activation but is also expressed by astrocytes in some conditions and constitutively by endothelial cells. Therefore, our current understanding of neuroinflammation dynamics is hampered by the lack of alternative targets available for PET imaging. We performed a systematic search and review on radiotracers developed for neuroinflammation PET imaging apart from TSPO. The following targets of interest were identified through literature screening (including previous narrative reviews): P2Y12R, P2X7R, CSF1R, COX (microglial targets), MAO-B, I2BS (astrocytic targets), CB2R & S1PRs (not specific of a single cell type). We determined the level of development and provided a scoping review for each target. Strikingly, astrocytic biomarker MAO-B has progressed in clinical investigations the furthest, while few radiotracers (notably targeting S1P1Rs, CSF1R) are being implemented in clinical investigations. Other targets such as CB2R and P2X7R have proven disappointing in clinical studies (e.g. poor signal, lack of changes in disease conditions, etc.). While astrocytic targets are promising, development of new biomarkers and tracers specific for microglial activation has proven challenging.
Collapse
Affiliation(s)
- Fabien Chauveau
- Université Claude Bernard Lyon 1, Centre de Recherche en Neurosciences de Lyon, Inserm U1028, CNRS UMR5292, BIORAN, Groupement Hospitalier Est - CERMEP, 59 boulevard Pinel, 69677, Bron, Cedex, France
| | - Alexandra Winkeler
- Université Paris-Saclay, Inserm, CNRS, CEA, BioMaps, Service Hospitalier Frédéric Joliot, 4 place du général Leclerc, 91401, Orsay, France
| | - Sylvie Chalon
- UMR 1253 iBrain, Université de Tours - INSERM, Bâtiment Planiol, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours, Cedex 01, France
| | - Hervé Boutin
- UMR 1253 iBrain, Université de Tours - INSERM, Bâtiment Planiol, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours, Cedex 01, France.
| | - Guillaume Becker
- Université Claude Bernard Lyon 1, Centre de Recherche en Neurosciences de Lyon, Inserm U1028, CNRS UMR5292, BIORAN, Groupement Hospitalier Est - CERMEP, 59 boulevard Pinel, 69677, Bron, Cedex, France
- Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail, 14 rue Pierre et Marie Curie, 94701, Maisons-Alfort, Cedex, France
| |
Collapse
|
4
|
Gentili F, Cardinaletti C, Vesprini C, Ghelfi F, Farande A, Giannella M, Piergentili A, Quaglia W, Mattioli L, Perfumi M, Hudson A, Pigini M. Novel Ligands Rationally Designed for Characterizing I2−Imidazoline Binding Sites Nature and Functions. J Med Chem 2008; 51:5130-4. [DOI: 10.1021/jm800400k] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Francesco Gentili
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Claudia Cardinaletti
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Cristian Vesprini
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Francesca Ghelfi
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Aniket Farande
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Mario Giannella
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Alessandro Piergentili
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Wilma Quaglia
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Laura Mattioli
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Marina Perfumi
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Alan Hudson
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| | - Maria Pigini
- Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino 1, 62032 Camerino, Italy, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Università degli Studi di Camerino, via Madonna delle Carceri, 62032 Camerino, Italy, Department of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
5
|
Sa̧czewski F, Kornicka A, Rybczyńska A, Hudson AL, Miao SS, Gdaniec M, Boblewski K, Lehmann A. 1-[(Imidazolidin-2-yl)imino]indazole. Highly α2/I1 Selective Agonist: Synthesis, X-ray Structure, and Biological Activity. J Med Chem 2008; 51:3599-608. [DOI: 10.1021/jm800112s] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Franciszek Sa̧czewski
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Anita Kornicka
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Apolonia Rybczyńska
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Alan L. Hudson
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Shu Sean Miao
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Maria Gdaniec
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Konrad Boblewski
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| | - Artur Lehmann
- Department of Chemical Technology of Drugs and Department of Pathophysiology, Medical University of Gdańsk, 80-416 Gdańsk, Poland, Department of Pharmacology, University of Alberta, Edmonton, T6G 2R3, Canada, and Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
| |
Collapse
|